Showing recent highlights
Guidelines
PubMed · October 13, 2026
According to American Academy of Neurology (AAN) and American Headache Society guidelines, doctors should carefully weigh when to start a preventive migraine medication — meaning a daily medication taken to reduce how often migraines happen — and which one fits best for each person's specific situation, such as whether they also have high blood pressure, obesity, or are pregnant. The guidelines also give doctors guidance on how to tell if a preventive medication is actually working and when it makes sense to stop it. This matters because choosing the right preventive medication for the right person can meaningfully reduce the burden of migraines on someone's daily life.
Ask your doctor: Ask the doctor whether the patient should start taking a daily preventive migraine medication based on how often the patient gets migraines and whether other treatments have worked.
Guidelines
PubMed · October 13, 2026
According to the American Academy of Neurology (AAN) and the American Headache Society guidelines, several medications are strongly recommended for preventing migraines in adults — including galcanezumab and erenumab (injectable monthly medications), as well as options like propranolol (a blood pressure medication), topiramate (originally a seizure medication), and others. These recommendations matter because preventing migraines before they start can meaningfully reduce how often people experience them each month, which can make a real difference in daily quality of life. People who have frequent migraines may want to ask their doctor whether a preventive medication could be right for them.
Ask your doctor: Ask the doctor whether the patient should try a migraine prevention medication like topiramate or propranolol based on how many migraines the patient is having each month.
What's New
PubMed · September 1, 2026
A study found that people with episodic migraine — meaning migraines that come and go rather than happening most days — who used a biofeedback app on their phone for 12 weeks had about one fewer migraine day per month compared to those who didn't use it. Biofeedback is a technique where you learn to notice and gently control body signals like muscle tension or heart rate, and in this case it was done entirely through a smartphone app without any clinic visits. People using the app also reported feeling better overall in their daily lives, and the side effects were mild. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · September 1, 2026
A study found that a migraine prevention medication called atogepant (brand name Qulipta) was compared head-to-head with an older migraine prevention medication called topiramate. Researchers found that people taking atogepant were less likely to stop their medication due to side effects, suggesting it may be better tolerated than topiramate. This is noteworthy because it's one of the first studies to directly compare these two types of migraine prevention treatments against each other, giving doctors more information to help choose the right option for their patients.
Ask your doctor: Ask the doctor whether atogepant might work better than topiramate for preventing the patient's migraines with fewer side effects.
What's New
PubMed · September 1, 2026
Researchers found that people with migraine in Japan taking a monthly injection called erenumab reported that their most troublesome symptoms — intense pain, nausea, and deep exhaustion — interfered heavily with work, school, household tasks, and emotional wellbeing before treatment, and that many felt meaningful improvements in their day-to-day lives after using it. This matters because it gives a clearer picture of how migraine affects real people beyond just the number of headache days, capturing the emotional and practical toll that often goes unmentioned in doctor's visits. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · September 1, 2026
A study found that people with migraines who practiced a specific yoga breathing technique — called alternate nostril breathing, done for just 20 minutes — showed immediate improvements in two areas: visuospatial cognition (the brain's ability to process and remember visual patterns and spatial information) and interoceptive accuracy (how well a person can sense what's happening inside their own body, like noticing their own heartbeat). Researchers compared this group to people who simply watched a documentary for the same amount of time, and the breathing group came out ahead on both measures right after the session. This suggests that a single, short yoga breathing session may offer quick mental and body-awareness benefits for people who experience migraines.
What's New
PubMed · August 28, 2026
A study found that a short online therapy program — based on a talk-therapy approach called CBT (Cognitive Behavioral Therapy) — helped people with frequent migraines worry less about their pain, a pattern researchers call 'pain catastrophizing,' meaning the tendency to expect the worst when pain strikes. Importantly, the less people catastrophized about their pain, the less their migraines interfered with their daily lives. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 15, 2026
Researchers found that spending more time looking at digital screens — phones, computers, tablets, and similar devices — was linked to a higher chance of getting migraines or headaches more often and more severely. The review pulled together findings from many studies across children, teens, and adults, making it one of the more thorough looks at this connection so far. This could matter for people with migraines because screen time is something many people can adjust in their daily lives, though exactly how screens trigger attacks is still being studied. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · August 1, 2026
Researchers found that eating a low-carbohydrate diet built around plant foods — think vegetables, nuts, legumes, and whole grains, while cutting back heavily on bread, sugar, and starchy foods — helped people with obesity or related health conditions lose roughly 5 to 7 kilograms (about 11 to 15 pounds). The same approach also lowered harmful LDL cholesterol and improved blood sugar level (A1C), which measures how well the body has been managing blood sugar over the past few months. These results came from seven studies involving nearly 1,000 adults and lasted anywhere from about one month to one year.
What's New
PubMed · August 1, 2026
Researchers found that eye drops containing a numbing medicine called tetracaine — the kind used to numb the surface of the eye — helped reduce migraine pain significantly faster than a fake drop in people treated in the emergency department, with pain scores dropping noticeably within just one minute. However, many patients who received the tetracaine drops experienced temporary blurred vision and eye irritation. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people who are natural 'night owls' — meaning they feel most alert in the evening and tend to go to bed late — were about 67% more likely to report living with chronic pain compared to people who naturally wake early or keep more typical schedules. This pattern showed up across many types of pain, including muscle and joint pain and headache disorders, after combining results from 43 separate studies. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that medical hypnosis — a guided technique that helps people deeply focus their attention and use mental imagery — may help reduce how often migraines happen and how painful they are, sometimes working better than other non-drug approaches. This finding comes from a review of nine smaller studies involving 406 people with migraines. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with migraine who also experience depression or anxiety tend to have more frequent headaches — and this connection showed up consistently across dozens of studies involving over 70,000 people. Other emotional and psychological factors, like fear of pain and a person's belief in their own ability to cope (sometimes called self-efficacy), were also linked to how much migraines disrupted daily life. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 29, 2026
Researchers found that blood-thinning medications — including aspirin, clopidogrel, and rivaroxaban — may help reduce migraine frequency in people who have a small natural opening in the heart called a patent foramen ovale (PFO), which is a hole between the heart's upper chambers that didn't fully close after birth. The study compared these blood-thinning drugs against a blood pressure medication and looked at how many people saw their migraine days cut in half over about three months. This could matter because it suggests the heart's structure might play a role in some people's migraines, potentially opening the door to different treatment approaches — though this is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient should consider taking a blood thinner like aspirin to help prevent migraines, since the patient has a patent foramen ovale.
What's New
PubMed · July 23, 2026
Researchers found that people with migraine don't just suffer during a headache — they also carry a hidden burden in the quiet time *between* attacks, including anxiety, brain fog, avoiding social situations, and changing daily behaviors out of fear that a new attack might strike. This matters because it means the true impact of migraine on someone's life is likely being underestimated when doctors only focus on the attacks themselves. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that people who are naturally wired to stay up late and wake up later — often called 'evening types' or night owls — were about 54% more likely to experience chronic pain, including headaches, back pain, and muscle or joint pain, compared to people with earlier sleep patterns. This connection held up across 18 different studies, suggesting that when a person's internal body clock is out of sync with their daily schedule, it may play a real role in how much pain they experience. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that people with migraines who used a digital app called sinCephalea — which tracks how their blood sugar responds to different foods and suggests personalized low-sugar eating patterns — had fewer migraine days per month compared to people who used a standard app. The benefit was especially noticeable among people who closely followed the app's eating recommendations, suggesting that keeping blood sugar (the level of sugar in your blood) steady through personalized nutrition might help reduce how often migraines occur. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that injecting a numbing or muscle-relaxing medication directly near a nerve at the back of the head — guided by ultrasound so the doctor can see exactly where to place the needle — may help prevent frequent migraines just as well as taking daily medication. The study looked at people who had migraines on 15 or more days per month, which is a level that can seriously disrupt everyday life, and tracked how they felt over three months using measures of pain impact, mood, and quality of life. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that acupuncture may work just as well as standard medications for reducing migraine pain and lowering the number of migraine days per month, while also causing fewer side effects. This could matter for people with migraine who want to explore options beyond medication, or who have had trouble tolerating medication side effects. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that fremanezumab, an injection used to prevent migraines, helped people with migraine have nearly 6 fewer migraine days per month after just one month of treatment, with results continuing to improve over a year. About half of patients saw their migraine days cut in half within three months, and the medication was generally well tolerated, with constipation being the most commonly reported side effect. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that about 1 in 3 children and teens being treated with medication to prevent migraines experienced at least one unwanted side effect — things like fatigue, mood changes, or other reactions depending on the drug. Some medications had higher rates of side effects than others, raising questions about how safe and worthwhile these treatments are for younger people, whose growing bodies can be more sensitive. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 26, 2026
A study found that migraine may not fall neatly into two separate categories — 'episodic' (occasional) and 'chronic' (frequent) — but instead might be better understood as one condition that ranges from mild and infrequent all the way to severe and near-daily, with symptoms and life impact gradually worsening along that spectrum. Researchers analyzed data from over 10,000 adults with migraine across 14 countries and found that the more migraine days someone experienced each month, the more their quality of life and ability to participate in daily activities suffered — with no clear cutoff point where one 'type' ended and another began. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · June 13, 2026
A study found that eptinezumab — sold under the brand name Vyepti, given as an IV infusion — helped reduce how often and how severely migraines occurred in people who had both chronic migraine and a condition called medication-overuse headache, where taking too many pain relievers actually causes more headaches over time. Researchers found these benefits held up over 24 weeks, and participants also reported feeling better in their daily lives. This appears to be a new finding about how well this treatment works for this specific combination of conditions, rather than a safety update or guideline change.
What's New
PubMed · June 9, 2026
Researchers found that a group of injectable migraine-prevention medications — ones that work by blocking a protein in the brain called CGRP, which is thought to trigger migraines — consistently helped people with chronic migraine (meaning 15 or more headache days a month) have fewer migraine days, even among patients who hadn't responded well to other treatments. The medications also appeared to be well-tolerated, meaning most people didn't have serious side effects. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 8, 2026
A study found that certain chemical signals in the body — including ones linked to inflammation and blood vessel activity — rise and fall at different stages of a migraine attack. Researchers also found that caffeine appeared to reduce some of these signals during an active migraine, particularly in people whose levels were highest to begin with, which may help explain why caffeine sometimes eases migraine pain. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed (Guideline Reviews) · June 5, 2026
According to guidelines from the American Society of Regional Anesthesia and Pain Medicine and several partner organizations, lower doses of corticosteroid (steroid) injections can work just as well as the higher doses that have traditionally been used for chronic pain procedures — which matters because these injections carry real risks, including raised blood sugar levels, weakening of bones over time, and effects on the body's natural hormone balance. The guidelines cover common pain procedures like nerve blocks and trigger point injections, looking closely at both how well they work and how to use them as safely as possible. People with chronic pain who receive these injections may want to ask their doctor about the dose being used and what side effects to watch for.
Ask your doctor: Ask the doctor whether lower doses of corticosteroid injections for the patient's chronic pain would work just as well as the standard doses while reducing risks like higher blood sugar and weaker bones.
What's New
PubMed · June 1, 2026
A study found that women with episodic migraine — meaning migraines that come and go rather than happening daily — who went through a type of talk therapy called Acceptance and Commitment Therapy showed interesting links between their stress hormone levels and how much their migraines affected daily life. Specifically, cortisol, a hormone the body releases in the morning as a kind of natural 'wake-up' signal, appeared to be connected to how disabled patients felt from their migraines and their mood. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that atogepant, a migraine prevention pill, reaches the fluid surrounding the brain and spinal cord in only very small amounts — less than 1% of the level found in the bloodstream. This matters because scientists have debated whether migraine medications need to enter the brain directly to work, and this finding suggests atogepant may be effective even while mostly staying outside the brain. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that about 1 in 5 people with migraine also experience restless legs syndrome — an uncomfortable urge to move the legs, often disrupting sleep. The connection was even stronger in people who have had migraines for a long time, those with more severe migraine-related disability, and those who experience migraine with aura (a kind of migraine often preceded by visual or sensory warning signs). This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a 6-week relaxation and biofeedback program — where patients learn to calm their body's stress response using real-time feedback — may work especially well for people with migraine who tend to worry a lot about physical discomfort in their bodies. People who worried more about bodily sensations at the start of the program seemed to get the biggest benefit in terms of migraine-related quality of life compared to those who just received standard self-management materials. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.